D-ALBA (GIMEMA LAL2116)
The trial that showed Ph-positive ALL can be treated with a pill plus an immunotherapy and no chemotherapy, with 95% of patients alive at 18 months.
63 patients (median age 54): molecular response 60% after two blinatumomab cycles rising with further cycles; 18-month OS 95%, DFS 88%; only half went to transplant. NEJM 2020. Four-year update: OS ~80%, DFS ~75%, with IKZF1-plus and T315I relapses. Successor trials (GIMEMA ALL2820 with ponatinib) and MD Anderson ponatinib-blinatumomab series extend the chemotherapy-free approach.
- 88 out of 100 people alive without the cancer coming back at 18 months with Dasatinib → blinatumomab.
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- 95 out of 100 people alive at 18 months with Dasatinib → blinatumomab.
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- There was no comparison group, so this number cannot tell you how much of the effect is due to the treatment.
- These results apply to the people the trial enrolled: Newly diagnosed Ph-positive ALL, adults of all ages: dasatinib induction followed by blinatumomab, no systemic chemotherapy. People in a different situation may not see the same effect.
- Only 63 people took part, so the numbers are less certain than in a large trial.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
63 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survival at 18 months | Dasatinib → blinatumomab | 63 | 95% | — | — | link |
| Disease-free survival at 18 monthsprimary | Dasatinib → blinatumomab | — | 88% | — | — | — |
Pages like this
not linked directly; found by shared links- ProductPonatinib
Shares BCR::ABL1 TKI + blinatumomab (chemotherapy-free Ph+ ALL), Transplant-free Ph-positive ALL for MRD-negative adults, Ph-positive ALL, BCR::ABL1 (Philadelphia chromosome).
- TrialPhALLCON
Shares BCR::ABL1 TKI + blinatumomab (chemotherapy-free Ph+ ALL), Ph-positive ALL, BCR::ABL1 (Philadelphia chromosome), Acute lymphoblastic leukaemia.
- TrialTOWER
Shares Blinatumomab, CD19, Acute lymphoblastic leukaemia.
- PersonRachel E. Rau
Shares Blinatumomab, CD19, Acute lymphoblastic leukaemia.
- ProductAsciminib
Shares Ph-positive ALL, BCR::ABL1 (Philadelphia chromosome), Acute lymphoblastic leukaemia.
- PersonMark R. Litzow
Shares Blinatumomab, CD19, Acute lymphoblastic leukaemia.
- PairingBlinatumomab added to frontline chemotherapy
Shares Blinatumomab, CD19, Acute lymphoblastic leukaemia.
- TermPhiladelphia chromosome (Ph+, BCR::ABL1)
Shares Dasatinib, Blinatumomab, Acute lymphoblastic leukaemia.